Overview
Life science tech firm's Q4 revenue rose 14% yr/yr, driven by record consumable sales
Adjusted net income for Q4 beat analyst expectations
Company completed sale of short-read sequencing assets, strengthening balance sheet
Outlook
Company plans to launch SPRQ-Nx to lower sequencing costs in 2026
PacBio aims to drive growth with strengthened balance sheet post asset sale
Company did not provide specific financial guidance for 2026
Result Drivers
RECORD CONSUMABLE SALES - Consumable revenue reached an all-time high, contributing significantly to Q4 revenue growth
ASSET SALE - Completed sale of short-read sequencing assets, strengthening balance sheet
DECLINE IN REVIO PLACEMENTS - Revio system placements decreased compared to the previous year
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Adjusted Net Income | Beat | -$37.60 mln | -$44.30 mln (4 Analysts) |
Q4 Adjusted Gross Profit | $17.80 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.00, about 8.7% above its February 11 closing price of $1.84
Press Release: ID:nGNX8cG9QQ
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)